Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials.

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials. Hematology Am Soc Hematol Educ Program. 2019 Dec 06;2019(1):476-481 Authors: Woyach JA Abstract The management of chronic lymphocytic leukemia (CLL) has undergone dramatic changes over the previous 2 decades with the introduction of multiple new therapies and new combinations. Management of the newly diagnosed asymptomatic patient has not significantly changed outside of the development of a number of prognostic factors and the CLL International Prognostic Index, which is helpful in discussions regarding prognosis and likelihood of requiring treatment. When therapy is required, initial treatment of most patients now includes either the Bruton tyrosine kinase inhibitor ibrutinib or the B-cell lymphoma 2 inhibitor venetoclax in combination with obinutuzumab. Current frontline trials are focused on the optimal sequencing or combination of targeted therapies. In this review, we will discuss the management of previously untreated CLL with an emphasis on the clinical trials that have formed the standard of care, as well as those newer studies that are likely to form the next generation of therapy. PMID: 31808904 [PubMed - in process]
Source: Hematology ASH Education Program - Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research

Related Links:

Conclusion: Our series details the unusual circumstances when an eye is removed for intraocular lymphoma. Different patterns of ocular tissue involvement were observed when we compared primary and secondary lymphomas.
Source: RETINA - Category: Opthalmology Tags: Clinicopathologic Correlation Source Type: research
Conditions:   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Small Lymphocytic Lymphoma Interventions:   Biological: Daratumumab;   Drug: Ibrutinib Sponsors:   Mayo Clinic;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS: LEF1 is not expressed in most CD5-positive MZLs and LPLs; therefore, it is a reliable marker for distinguishing them from CLL/SLL. LEF1 may be expressed in CD5-positive FLs. PMID: 31953940 [PubMed - as supplied by publisher]
Source: American Journal of Clinical Pathology - Category: Pathology Authors: Tags: Am J Clin Pathol Source Type: research
AbstractOne of the most common applications of clinical flow cytometry is to diagnose chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). When classic features are present and correlation with other diagnostic modalities is possible, the distinction of CLL/SLL from other subtypes of B-cell lymphoma is straightforward. However, features deviating from prototypical phenotypes occur not infrequently and can present a diagnostic dilemma. One potential pitfall that has not been well described is mimicry of CLL/SLL by mantle cell lymphoma. A review of flow cytometric data and corresponding clinical, morphologic, a...
Source: Journal of Hematopathology - Category: Pathology Source Type: research
Medicare beneficiaries saw unfavorable results when compared to clinical trial participants being treated with idelalisib for their follicular lymphoma or chronic lymphocytic leukemia.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Conditions:   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Small Lymphocytic Lymphoma Interventions:   Biological: Daratumumab;   Drug: Ibrutinib Sponsors:   Mayo Clinic;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Deterioration of hematologic parameters in lymphoma patients is often attributed to disease progression, comorbidities, or treatment effects. Second primary malignancies occur at increased frequency in CLL and must also be considered. AbstractDeterioration of hematologic parameters in lymphoma patients is often attributed to disease progression, comorbidities, or treatment effects. Second primary malignancies occur at increased frequency in CLL and must also be considered.
Source: Clinical Case Reports - Category: General Medicine Authors: Tags: CLINICAL IMAGE Source Type: research
Conclusions TMTV extracted from FDG PET at the time of the transformation of CLL into DLBCL is a predictor of OS.
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Original Articles Source Type: research
ConclusionsPTC risk was elevated after a range of first primary adult cancers but was not clearly related to treatment. Although surveillance may contribute to elevated short-term risks of PTC, longer-term elevations in regional/distant PTC may be attributable to shared risk factors.
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
THURSDAY, Dec. 26, 2019 -- For patients with chronic lymphocytic leukemia (CLL) in routine care, overall survival improved from 1995 to 2017, according to a study recently published in Leukemia&Lymphoma. Rudolf Weide, M.D., from the Praxis...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Chronic Leukemia | Chronic Lymphocytic Leukemia | Clinical Trials | Education | Hematology | Lessons | Leukemia | Lymphoma | Study | Universities & Medical Training